Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Post-Coronavirus Disease Mucormycosis: Predisposing Factors and Possible Treatment: A Narrative Review

Author(s): Sonali Sinhmar, Vandana Garg*, Hitesh Malhotra and Rohit Dutt

Volume 3, Issue 6, 2022

Published on: 23 December, 2022

Article ID: e210622206253 Pages: 8

DOI: 10.2174/2666796703666220621145437

Price: $65

Abstract

Mucormycosis, commonly known as black fungus, is a life-threatening fungal infection belonging to the order Mucorales. It affects individuals with an impaired immune response or immune disorders such as diabetes mellitus, induced immunosuppression, hematological cancers, acquired immune deficiency syndrome, or who have undergone organ transplantation. The symptoms of black fungus include difficulty in breathing, blurred vision, coughing out blood, chest pain, and blackening over the area of the nose. Tissue necrosis is the main symptom of this infection . Its prevalence is increasing day by day and has been observed in vulnerable patients, including patients suffering from COVID-19 (coronavirus) and those who have been recovered. It has been observed that black fungus cases are increasing in recovered COVID patients, and various cases of white and yellow fungus are also reported. The treatment approach includes the use of antifungal agents, triazoles, surgery, combination therapy, etc. This review describes the clinical manifestation, predisposing factors, and treatment strategies of mucormycosis.

Keywords: Mucormycosis, COVID, diabetes, immunity, risk factors, pulmonary mucormycosis, Cutaneousmucormycosis.

Graphical Abstract

[1]
Fürbringer P. Observations on pulmonary mycosis in man. Virchows Arch 1876; 66(3): 330-65.
[http://dx.doi.org/10.1007/BF01878266]
[2]
deShazo RD. Fungal sinusitis. Am J Med Sci 1998; 316(1): 39-45.
[PMID: 9671042]
[3]
Black fungus complicates India’s COVID pandemic. Available from: https://www.news-medical.net/news/20210513/Black-fungus-complicates-Indias-COVID-pandemic.aspx
[4]
Torres-Narbona M, Guinea J, Martínez-Alarcón J, Muñoz P, Gadea I, Bouza E. Impact of zygomycosis on microbiology workload: A survey study in Spain. J Clin Microbiol 2007; 45(6): 2051-3.
[http://dx.doi.org/10.1128/JCM.02473-06] [PMID: 17392438]
[5]
Zaoutis TE, Roilides E, Chiou CC, et al. Zygomycosis in children: A systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26(8): 723-7.
[http://dx.doi.org/10.1097/INF.0b013e318062115c] [PMID: 17848885]
[6]
Gupta KL, Khullar DK, Behera D, Radotra BD, Sakhuja V. Pulmonary mucormycosis presenting as fatal massive haemoptysis in a renal transplant recipient. Nephrol Dial Transplant 1998; 13(12): 3258-60.
[http://dx.doi.org/10.1093/ndt/13.12.3258] [PMID: 9870509]
[7]
Kitabayashi A, Hirokawa M, Yamaguchi A, Takatsu H, Miura AB. Invasive pulmonary mucormycosis with rupture of the thoracic aorta. Am J Hematol 1998; 58(4): 326-9.
[http://dx.doi.org/10.1002/(SICI)1096-8652(199808)58:4<326:AID-AJH13>3.0.CO;2-5] [PMID: 9692398]
[8]
Passamonte PM, Dix JD. Nosocomial pulmonary mucormycosis with fatal massive hemoptysis. Am J Med Sci 1985; 289(2): 65-7.
[http://dx.doi.org/10.1097/00000441-198502000-00005] [PMID: 3976712]
[9]
Connor BA, Anderson RJ, Smith JW. Mucor mediastinitis. Chest 1979; 75(4): 525-6.
[http://dx.doi.org/10.1378/chest.75.4.524] [PMID: 446151]
[10]
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41(5): 634-53.
[http://dx.doi.org/10.1086/432579] [PMID: 16080086]
[11]
Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17(12): 1859-67.
[http://dx.doi.org/10.1111/j.1469-0691.2010.03456.x] [PMID: 21199154]
[12]
Hosseini SM, Borghei P. Rhinocerebral mucormycosis: Pathways of spread. Eur Arch Otorhinolaryngol 2005; 262(11): 932-8.
[http://dx.doi.org/10.1007/s00405-005-0919-0] [PMID: 15891927]
[13]
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13(2): 236-301.
[http://dx.doi.org/10.1128/CMR.13.2.236] [PMID: 10756000]
[14]
Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18(3): 556-69.
[http://dx.doi.org/10.1128/CMR.18.3.556-569.2005] [PMID: 16020690]
[15]
Chawla R, Sehgal S, Kumar SR, Mishra B. A rare case of mucormycosis of median sternotomy wound caused by Rhizopus arrhizus. Indian J Med Microbiol 2007; 25(4): 419-21.
[http://dx.doi.org/10.1016/S0255-0857(21)02067-3] [PMID: 18087101]
[16]
Kordy FN, Al-Mohsen IZ, Hashem F, Almodovar E, Al Hajjar S, Walsh TJ. Successful treatment of a child with posttraumatic necrotizing fasciitis caused by Apophysomyces elegans: Case report and review of literature. Pediatr Infect Dis J 2004; 23(9): 877-9.
[http://dx.doi.org/10.1097/01.inf.0000136870.17071.fd] [PMID: 15361732]
[17]
Ibrahim A, Edwards JE Jr, Filler SG, Eds. Mucormycosis. Philadelphia: Harcourt Brace 2004.
[18]
Oliver MR, Van Voorhis WC, Boeckh M, Mattson D, Bowden RA. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996; 22(3): 521-4.
[http://dx.doi.org/10.1093/clinids/22.3.521] [PMID: 8852973]
[19]
Ismail MH, Hodkinson HJ, Setzen G, Sofianos C, Hale MJ. Gastric mucormycosis. Trop Gastroenterol 1990; 11(2): 103-5.
[PMID: 2219440]
[20]
Virk SS, Singh RP, Arora AS, Grewal JS, Puri H. Gastric zygomycosis-an unusual cause of massive upper gastrointestinal bleed. Indian J Gastroenterol 2004; 23(4): 146-7.
[PMID: 15333973]
[21]
Cherney CL, Chutuape A, Fikrig MK. Fatal invasive gastric mucormycosis occurring with emphysematous gastritis: Case report and literature review. Am J Gastroenterol 1999; 94(1): 252-6.
[http://dx.doi.org/10.1111/j.1572-0241.1999.00809.x] [PMID: 9934766]
[22]
Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10 (Suppl. 1): 31-47.
[http://dx.doi.org/10.1111/j.1470-9465.2004.00843.x] [PMID: 14748801]
[23]
Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002; 16(4): 895-914.
[http://dx.doi.org/10.1016/S0891-5520(02)00037-5] [PMID: 12512186]
[24]
McNab AA, McKelvie P. Iron overload is a risk factor for zygomycosis. Arch Ophthalmol 1997; 115(7): 919-21.
[http://dx.doi.org/10.1001/archopht.1997.01100160089018] [PMID: 9230837]
[25]
Sanchez-Recalde A, Merino JL, Dominguez F, Mate I, Larrea JL, Sobrino JA. Successful treatment of prosthetic aortic valve mucormycosis. Chest 1999; 116(6): 1818-20.
[http://dx.doi.org/10.1378/chest.116.6.1818] [PMID: 10593814]
[26]
Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomycosis: Report of four cases and review. Rev Infect Dis 1989; 11(5): 741-54.
[http://dx.doi.org/10.1093/clinids/11.5.741] [PMID: 2682947]
[27]
Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019; 25(1): 26-34.
[http://dx.doi.org/10.1016/j.cmi.2018.07.011] [PMID: 30036666]
[28]
Skiada A, Petrikkos G. Cutaneous mucormycosis. Skinmed 2013; 11(3): 155-9.
[PMID: 23930354]
[29]
Bhansali A, Bhadada S, Sharma A, et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J 2004; 80(949): 670-4.
[http://dx.doi.org/10.1136/pgmj.2003.016030] [PMID: 15537854]
[30]
Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50(1): 96-103.
[http://dx.doi.org/10.1128/AAC.50.1.96-103.2006] [PMID: 16377673]
[31]
Mok CC, Que TL, Tsui EY, Lam WY. Mucormycosis in systemic lupus erythematosus. Semin Arthritis Rheum 2003; 33(2): 115-24.
[http://dx.doi.org/10.1016/S0049-0172(03)00081-7] [PMID: 14625819]
[32]
Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006; 44(4): 335-42.
[http://dx.doi.org/10.1080/13693780500464930] [PMID: 16772227]
[33]
Patel A, Kaur H, Xess I, et al. A multicenter observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020; 26(7): 944.e9-944.e15.
[http://dx.doi.org/10.1016/j.cmi.2019.11.021]
[34]
Chakrabarti A, Singh R. Mucormycosis in India: Unique features. Mycoses 2014; 57 (Suppl. 3): 85-90.
[http://dx.doi.org/10.1111/myc.12243] [PMID: 25187095]
[35]
Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol 2019; 57(4): 395-402.
[http://dx.doi.org/10.1093/mmy/myy060] [PMID: 30085158]
[36]
Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: A novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008; 21(6): 620-5.
[http://dx.doi.org/10.1097/QCO.0b013e3283165fd1] [PMID: 18978530]
[37]
Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: Transferrin and iron availability. Diabetes 1982; 31(12): 1109-14.
[http://dx.doi.org/10.2337/diacare.31.12.1109] [PMID: 6816646]
[38]
Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry. Am J Kidney Dis 1991; 18(6): 660-7.
[http://dx.doi.org/10.1016/S0272-6386(12)80606-8] [PMID: 1962650]
[39]
Sugar AM. Mucormycosis. Clin Infect Dis 1992; 14 (Suppl. 1): S126-9.
[http://dx.doi.org/10.1093/clinids/14.Supplement_1.S126] [PMID: 1562684]
[40]
Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of zygomycetes organisms following exposure to voriconazole: A study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199(9): 1399-406.
[http://dx.doi.org/10.1086/597615] [PMID: 19358672]
[41]
Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough invasive mold infections in the hematology patient: Current concepts and future directions. Clin Infect Dis 2018; 67(10): 1621-30.
[http://dx.doi.org/10.1093/cid/ciy473] [PMID: 29860307]
[42]
Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118(5): 1216-24.
[http://dx.doi.org/10.1182/blood-2011-03-316430] [PMID: 21622653]
[43]
Antinori S, Nebuloni M, Magni C, et al. Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: A retrospective study of 1,630 autopsies performed between 1984 and 2002. Am J Clin Pathol 2009; 132(2): 221-7.
[http://dx.doi.org/10.1309/AJCPRAAE8LZ7DTNE] [PMID: 19605816]
[44]
Van den Saffele JK, Boelaert JR. Zygomycosis in HIV-positive patients: A review of the literature. Mycoses 1996; 39(3-4): 77-84.
[http://dx.doi.org/10.1111/j.1439-0507.1996.tb00106.x] [PMID: 8766998]
[45]
Nagy-Agren SE, Chu P, Smith GJ, Waskin HA, Altice FL. Zygomycosis (mucormycosis) and HIV infection: Report of three cases and review. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10(4): 441-9.
[http://dx.doi.org/10.1097/00042560-199512000-00007] [PMID: 7583440]
[46]
Sanchez MR, Ponge-Wilson I, Moy JA, Rosenthal S. Zygomycosis and HIV infection. J Am Acad Dermatol 1994; 30(5 Pt 2): 904-8.
[http://dx.doi.org/10.1016/S0190-9622(94)70110-5] [PMID: 8169272]
[47]
Blatt SP, Lucey DR, DeHoff D, Zellmer RB. Rhinocerebral zygomycosis in a patient with AIDS. J Infect Dis 1991; 164(1): 215-6.
[http://dx.doi.org/10.1093/infdis/164.1.215] [PMID: 2056212]
[48]
Wuhan City Health Committee. Wuhan municipal health and health commission’s briefing on the current pneumonia epidemic situation in our city 2019. Available from: http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989 [Accessed on: 14 January 2020]
[49]
Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial superinfections among persons with coronavirus disease 2019: A comprehensive review of data from postmortem studies. Open Forum Infect Dis 2021; 8(3): ofab065.
[50]
Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med 2020; 8(6): e48-9.
[http://dx.doi.org/10.1016/S2213-2600(20)30237-X] [PMID: 32445626]
[51]
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). Treasure Island, FL: StatPearls Publishing 2022.
[52]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of COVID-19 - Final Report. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[53]
Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA 2020; 324(13): 1330-41.
[http://dx.doi.org/10.1001/jama.2020.17023] [PMID: 32876694]
[54]
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384(8): 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]
[55]
Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020; 12(9): e10726.
[PMID: 33145132]
[56]
Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42(264): 264.e5-8.
[http://dx.doi.org/10.1016/j.ajem.2020.09.032] [PMID: 32972795]
[57]
Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg 2021; 37(2): e40-80.
[http://dx.doi.org/10.1097/IOP.0000000000001889] [PMID: 33229953]
[58]
Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: A tale of two pathogens. Indian J Ophthalmol 2021; 69(2): 244-52.
[http://dx.doi.org/10.4103/ijo.IJO_3774_20] [PMID: 33463566]
[59]
Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus 2021; 13(2): e13163.
[http://dx.doi.org/10.7759/cureus.13163] [PMID: 33575155]
[60]
India reports 40,854 cases of black fungus so far 2022. Available from: https://www.livemint.com/news/india-records-over-40k-cases-of-mucormycosis-11624875874985.html
[61]
Delhi had more active cases of black fungus than those of COVID-19: Govt data 2021. Available from: https://www.hindustantimes.com/cities/delhi-news/delhi-had-more-active-cases-of-black-fungus-than-those-of-covid-19-govt-data-101626231095524.html
[62]
Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012; 54 (Suppl. 1): S55-60.
[http://dx.doi.org/10.1093/cid/cir868] [PMID: 22247446]
[63]
Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47(4): 503-9.
[http://dx.doi.org/10.1086/590004] [PMID: 18611163]
[64]
Gamaletsou MN, Sipsas NV, Roilides E, Walsh TJ. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep 2012; 14(4): 423-34.
[http://dx.doi.org/10.1007/s11908-012-0272-6] [PMID: 22684277]
[65]
Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017; 102(3): 433-44.
[http://dx.doi.org/10.3324/haematol.2016.152900] [PMID: 28011902]
[66]
Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20 (Suppl. 3): 5-26.
[http://dx.doi.org/10.1111/1469-0691.12371] [PMID: 24479848]
[67]
Godoy MCB, Viswanathan C, Marchiori E, et al. The reversed halo sign: Update and differential diagnosis. Br J Radiol 2012; 85(1017): 1226-35.
[http://dx.doi.org/10.1259/bjr/54532316] [PMID: 22553298]
[68]
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016; 16(7): 828-37.
[http://dx.doi.org/10.1016/S1473-3099(16)00071-2] [PMID: 26969258]
[69]
Nagappan V, Deresinski S. Reviews of anti-infective agents: Posaconazole: A broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45(12): 1610-7.
[http://dx.doi.org/10.1086/523576] [PMID: 18190324]
[70]
Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. Mucormycosis treated with posaconazole: Review of 96 case reports. Crit Rev Microbiol 2013; 39(3): 310-24.
[http://dx.doi.org/10.3109/1040841X.2012.711741] [PMID: 22917084]
[71]
AstellasPharma US. Prescribing information for isavuconazonium sulfate Available from: https://www. astellas.us/docs/cresemba.pdf (Accessed on 1 July 2018).
[72]
Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order. Antimicrob Agents Chemother 2015; 59(12): 7735-42.
[http://dx.doi.org/10.1128/AAC.01919-15] [PMID: 26438494]
[73]
Spellberg B, Ibrahim A, Roilides E, et al. Combination therapy for mucormycosis: Why, what, and how? Clin Infect Dis 2012; 54 (Suppl. 1): S73-8.
[http://dx.doi.org/10.1093/cid/cir885] [PMID: 22247449]
[74]
Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47(3): 364-71.
[http://dx.doi.org/10.1086/589857] [PMID: 18558882]
[75]
Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries. Haematologica 2013; 98(10): e127-30.
[http://dx.doi.org/10.3324/haematol.2012.083063] [PMID: 23716556]
[76]
Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: The last 30 years. Arch Intern Med 1999; 159(12): 1301-9.
[http://dx.doi.org/10.1001/archinte.159.12.1301] [PMID: 10386506]
[77]
Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: Results of medical and surgical therapy. Ann Thorac Surg 1994; 57(4): 1044-50.
[http://dx.doi.org/10.1016/0003-4975(94)90243-7] [PMID: 8166512]
[78]
Vironneau P, Kania R, Morizot G, et al. Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival. Clin Microbiol Infect 2014; 20(5): O336-9.
[http://dx.doi.org/10.1111/1469-0691.12408] [PMID: 24118291]
[79]
Tragiannidis A, Groll AH. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. Clin Microbiol Infect 2009; 15 (Suppl. 5): 82-6.
[http://dx.doi.org/10.1111/j.1469-0691.2009.02986.x] [PMID: 19754764]
[80]
Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988; 10(3): 551-9.
[http://dx.doi.org/10.1093/clinids/10.3.551] [PMID: 3393782]
[81]
Shafer MR. Use of hyperbaric oxygen as adjunct therapy to surgical debridement of complicated wounds. Semin Perioper Nurs 1993; 2(4): 256-62.
[PMID: 8054952]
[82]
Price JC, Stevens DL. Hyperbaric oxygen in the treatment of rhinocerebral mucormycosis. Laryngoscope 1980; 90(5 Pt 1): 737-47.
[http://dx.doi.org/10.1288/00005537-198005000-00002] [PMID: 7374303]
[83]
Kajs-Wyllie M. Hyperbaric oxygen therapy for rhinocerebral fungal infection. J Neurosci Nurs 1995; 27(3): 174-81.
[http://dx.doi.org/10.1097/01376517-199506000-00006] [PMID: 7561264]
[84]
Couch L, Theilen F, Mader JT. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg 1988; 114(7): 791-4.
[http://dx.doi.org/10.1001/archotol.1988.01860190095032] [PMID: 3382536]
[85]
Barratt DM, Van Meter K, Asmar P, et al. Hyperbaric oxygen as an adjunct in zygomycosis: Randomized controlled trial in a murine model. Antimicrob Agents Chemother 2001; 45(12): 3601-2.
[http://dx.doi.org/10.1128/AAC.45.12.3601-3602.2001] [PMID: 11709348]
[86]
John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005; 11(7): 515-7.
[http://dx.doi.org/10.1111/j.1469-0691.2005.01170.x] [PMID: 15966968]
[87]
Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005; 191(7): 1180-7.
[http://dx.doi.org/10.1086/428503] [PMID: 15747255]
[88]
Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother 2011; 55(10): 4652-8.
[http://dx.doi.org/10.1128/AAC.00291-11] [PMID: 21825291]
[89]
Novel antifungal gains fast track designation for seven indications 2019. Available from: https://www.empr.com/home/news/drugsin-the-pipeline/novel-antifungal-gains-fast-track-designation-forseven-indications/ (accessed May 19, 2020).
[90]
Fothergill AW, McCarthy DI, Sutton DA, et al. The fungal Cyp51 inhibitor VT-1161 demonstrates in vitro synergy with tacrolimus against Aspergillus spp. and members of the order mucorales. In: Proceedings of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA. 2014.
[91]
India’s. ‘White fungus’ infections raise new health concerns. 2021. Available from: https://www.dw.com/en/covid-indias-white-fungus-infections-raise-new-health-concerns/a-57657371
[92]
How yellow fungus is different from white and black fungus: Cause, symptom, risks and treatment 2021. Available from: https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/how-yellow-fungus-is different-from-white-fungus-and-black-fungus-causes-symptoms-risks-and treatment/photostory/82944236.cms?picid=82944247

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy